BNTX:NASDAQ
BioNTech SE - ADR
$90.00
arrow_downward
-0.23%(-0.21) 1D
$89.06
arrow_downward
-1.04% (-0.94)todayPre-market
Closed: Jun 25, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$90.21
High
$90.99
Low
$89.42
Mkt. cap
22.76B
Avg. vol.
1.02M
Volume
1.60K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$5.76
Beta
1.30
Shares outstanding
252.88M
No. of employees
8K
Open
$90.21
High
$90.99
Low
$89.42
Mkt. cap
22.76B
Avg. vol.
1.02M
Volume
1.60K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$5.76
Beta
1.30
Shares outstanding
252.88M
No. of employees
8K
News stories
From sources across the web
Simply Wall Street
·
3 minutes ago
Affirm (AFRM) Teams Up With Backcountry To Bring Flexible Payments To Outdoor Shoppers
Foreign Policy Journal
·
5 minutes ago
NASA Awards AiRANACULUS $5M Contract To Build Next-Generation Lunar Communications Networks With (NASDAQ: NVDA), (NASDAQ: DELL), (NASDAQ: SMCI) And Partners
TheIndustry.fashion
·
58 minutes ago
Reformation files for NYSE IPO as revenue tops $500m
Yahoo Finance
·
30 minutes ago
Is Buying a Single S&P 500 ETF Enough for Your Portfolio?
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR
AI content may include mistakes. Learn more